Skip to main content
. Author manuscript; available in PMC: 2023 Aug 6.
Published in final edited form as: Cancer Discov. 2023 Feb 6;13(2):312–331. doi: 10.1158/2159-8290.CD-22-0686

Figure 2: JAK1 mutations do not confer primary resistance to PD-1 checkpoint immunotherapy.

Figure 2:

A. Mutation profiles of pre-treatment tumors, filtered for predicted pathogenic or deleterious mutations.

B. Association between individual mutations and response to PD-1 immunotherapy. Data are expressed as log odds ratios. A pseudocount was added for ARID1A, as all patients with non-mutant ARID1A responded to ICB. Statistical significance was assessed by two-tailed Fisher’s exact test.

C. Association of ARID1A, CTCF and JAK1 mutations with PD-1 immunotherapy response.

D. JAK1-mutant cancer cell fractions (CCFs) in JAK1-mutant tumors, after clustering. Each point represents a unique JAK1 variant that was identified in a particular sample. Pre-treatment CCFs are annotated in purple, while post-treatment CCFs are in green, with arrows connecting the same variant across timepoints.